2004年毕业于吉林大学药学本科专业，2010年获得吉林大学药理学专业博士学位，2008年至2010年赴瑞典Karolinska医学院学习。2011年至2013年在上海药物研究所新药研究国家重点实验室从事博士后研究工作，2013年起任上海药物研究所副研究员。

1. 中国科学院战略性先导科技专项项目：基于Stat3磷酸化抑制作用的个性化先导化合物的发现研究 

2. 上海市科委科技支撑项目：抗肿瘤PARP抑制剂JX系列化合物的成药性研究 

3. 国家自然科学基金青年科学基金项目：新型咪唑并杂环类化合物 MT189 的抗肿瘤作用及机制研究 

4. 中国博士后科学基金项目：新型有丝分裂抑制剂MT189抗肿瘤和新生血管生成抑制作用及机制研究 

1. Ying-Qing Wang#, Ping-Yuan Wang#, Yu-Ting Wang, Guang-Fu Yang, Ao Zhang*, and Ze-Hong Miao*. An update on PARP-1 inhibitors: opportunities and challenges in cancer therapy. Journal of Medicinal Chemistry. 2016, DOI: 10.1021/acs.jmedchem.6b00055. 

2. Jun-Mei Yi, Xia-Juan Huan, Shan-Shan Song, Hu Zhou, Ying-Qing Wang* and Ze-Hong Miao*. Triptolide induces cell killing in multidrug-resistant tumor Cells via CDK7/Rpb1 rather than XPB or p44. Molecular Cancer Therapeutics. 2016, 15(7):1495-1503.  

3. Yan Wang, Jia-Xin Li, Ying-Qing Wang*, Ze-Hong Miao*. Tanshinone I inhibits tumor angiogenesis by reducing stat3 phosphorylation at tyr705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells. Oncotarget. 2015, 6 (18): 16031-16042.  

4. Jun-Mei Yi，Xiao-Fei Zhang, Xia-Juan Huan, Shan-Shan Song, Wei Wang, Qian-Ting Tian, Yi-Ming Sun, Yi Chen, Jian Ding, Ying-Qing Wang*, Chun-Hao Yang* and Ze-Hong Miao*. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget. 2015, 6 (11): 8960-8973.  

5. Le-Le Zhao^#, Ying-Qing Wang^#, Dan-Yan Cao^#, Tian-Tian Chen, Qi Wang, Yan-Lian Li, Ye-Chun Xu, Nai-Xia Zhang, Xin Wang, Dan-Qi Chen, Lin Chen, Yue-Lei Chen, Guang-Xin Xia, Zhe Shi, Ze-Hong Miao*, Jing-Kang Shen*, Bing Xiong*. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. structure-based optimization. Jounal of Medicinal Chemistry. 2015, 58(3): 1281-1297. 

6. Ying-Qing Wang^#, Vijay Urmalia, Marie Bjornholm, Max Winerdal, Mattias Carlstrom, Bertil B. Fredholm*. Energy homeostasis in mice lacking adenosine receptors. Purinergic Signalling. 2014, 10 (4): 733-733. 

7. Wei Wang, Ying-Qing Wang, Tao Meng, Jun-Mei Yi, Xia-Juan Huan, Lan-Ping Ma, Lin-Jiang Tong, Yi Chen1, Jian Ding, Jing-Kang Shen, Ze-Hong Miao*. MCL-1 degradation mediated by JNK activation via MEKK1/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189. Molecular Cancer Therapeutics. 2014, 3 (6):1480-1491. 

8. Le-Le Zhao^#, Dan-Yan Cao^#, Tian-Tian Chen^#, Ying-Qing Wang^#, Ze-Hong Miao*, Ye-Chun Xu, Wu-Yan Chen, Xin Wang, Yan-Lian Li, Zhi-Yan Du, Bing Xiong*, Jian Li, Chun-Yan Xu, Nai-Xia Zhang, Jian-Hua He*, Jing-Kang Shen*. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. Journal of Medicinal Chemistry. 2013, 56 (10):3833-3851. 

9. Ying-Qing Wang^#, Ze-Hong Miao*. Marine-derived angiogenesis inhibitors for cancer therapy. Marine Drugs. 2013, 11(3): 903-933.  

10. Stefano Giustino Manzo^#, Zhao-Li Zhou^#, Ying-Qing Wang^#, Jessica Marinello, Jin-Xue He, Yuan-Chao Li, Jian Ding, Giovanni Capranico*, and Ze-Hong Miao*. Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Research. 2012, 72 (20): 5363-5373.